Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions Enters Into Collaboration Agreements with the NIH and Binghamton University to Develop Novel ADC

Collaboration with National Institutes of Health and Binghamton University to Develop Novel Antibody-Drug Conjugates for Pediatric Cancer https://www.issuewire.com/manhattan-biosolutions-enters-into-collaboration-agreements-with-the-nih-and-binghamton-university-to-develop-novel-adc-1781455477718844 New York City, New […]

Published March 10, 2022

Manhattan BioSolutions Announces Grant Award from the New Jersey CSIT

Fort Lee, New Jersey Mar 10, 2022 (Issuewire.com) – Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for […]

Published April 9, 2024

Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024

Published November 1, 2018

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University